Degenerative neurological disorders

Slowing disease progress primary concern for MS patients, survey finds


Courtesy of UCL

David Taylor, professor emeritus of pharmaceutical and public health policy at the University College London School of Pharmacy, said strategies based on early diagnosis and prompt access to treatment should improve treatment in the future

Efficacy is the greatest concern for patients with multiple sclerosis (MS) when they are considering treatment options, according to an international of more than 1000 people.

The survey, carried out by Bournemouth University and the consultancy Spoonful of Sugar, which works with medicines-related behaviour, found that slowing disease progression, along with improving symptoms and reducing relapses, trumped practical considerations, such as how and when a medication is taken in patients’ priorities.

Side effects and the possible long-term harms from medication were also important considerations for people with MS.

The survey included 1,040 patients living with MS in Australia, Canada, France, Germany, Italy, Spain, Sweden, the UK and the US, and aimed to explore their priorities and expectations from treatment.

It found that some people decided not to have medical treatment, even though disease-modifying therapies (DMTs) are available. The main reasons for this were concerns about the negative impacts of the treatment, such as side effects, as well as a lack of belief in treatment necessity.

When asked about their priorities, the results highlighted the impact of fatigue on the lives of people living with MS, with this most commonly cited as a symptom they would like treatment to reduce. Overall, patients wanted greater independence, including maintaining their mobility and alleviating bladder and bowel issues.

“All medicines carry risks and there are at present uncertainties about the long-term value of newer MS therapies,” said David Taylor, professor emeritus of pharmaceutical and public health policy at the University College London School of Pharmacy, who authored one of two based on the survey results.

“But strategies based on early diagnosis and prompt access to effective treatment should provide increasing future benefit, especially when accompanied by adequate investment in areas like rehabilitation and social care aimed at goals like helping people with MS stay in work and enjoy a fulfilling social life.”

Citation: The Salvadore DOI: 10.1211/PJ.2017.20204105

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

  • Minor Illness or Major Disease

    This established textbook helps you differentiate between minor illnesses which can be safely managed in the pharmacy, and major diseases.

  • Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

  • Biological Therapeutics

    An introduction to the treatment of disease using biological medicines derived from living plant and animal tissues.

  • Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete

Supplementary images

  • ms ct scan
  • david-taylor-professor-ucl-15

Jobs you might like

  • Scotland

  • Isle of Man (GB) (IM)

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.